Search
forLearn
5 / 801 resultslearn Spirulina
learn Beta glucan
learn Ciclopirox
learn ascorbic acid
Research
5 / 1000+ results
research Toxoplasma gondii infection and testosterone alteration: A systematic review and meta-analyses
Toxoplasma gondii infection may increase testosterone levels in males.
research Poxvirus and Toxoplasma gondii co-infection in a free-ranging Paraguayan hairy dwarf porcupine (Coendou spinosus), Brazil
Neotropical porcupines can get co-infected with poxvirus and Toxoplasma gondii.
research Differential transcriptome study on the damage of testicular tissues caused by chronic infection of T. gondii in mice
Chronic T. gondii infection may harm male fertility.
research Colchicine Therapy for Psoriasis
Sudden weight loss can cause significant hair loss, and using colchicine on the skin for psoriasis may be unsafe.
research Dermatophytosis caused by a Chrysosporium species in two cats in Turkey: a case report
Two cats and their owner in Turkey were successfully treated for a rare fungal infection with fluconazole.
Community Join
5 / 1000+ resultscommunity Another theory for hair loss: Parasites in gut.
Parasites in the gut may contribute to hair loss by depleting essential nutrients and disrupting hormone balance. An imbalance of hormones, not just DHT, could be a factor in androgenic alopecia.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
community So Pyrilutamide has been postponed by one year. How likely is that to happen to GT20029
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.